Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1990-08-14
1993-11-09
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514866, A61K 3702, A61K 3743
Patent
active
052602753
ABSTRACT:
Non-insulin dependent, or type 2, diabetes mellitus in a patient is treated by administering to the patient a hypoglycemic agent that enhances plasma concentrations of amylin and a therapeutically effective amount of an amylin antagonist. Hypoglycemic agents which enhance plasma concentrations of amylin can be sulfonylureas such as glibenclamide and tolbutamide. Amylin antagonists can be amylin 8-37 and CGRP 8-37. Administration of the amylin antagonist in conjunction with the hypoglycemic agent also enhances the blood glucose lowering effects of the hypoglycemic agent.
REFERENCES:
Leighton et al, "Pancreatic amylin and CGRP cause resistance to insulin . . . ", Nature 335:632-35 (1988).
Mitsukawa et al, "Islet Amyloid Polypeptide Response to Glucose, Insulin, . . . ", Diabetes, vol. 39, May 1990, pp. 639-642.
Moline et al, "Induction of Insulin Resistance In Vivo by Amylin and CRP", Diabetes, vol. 39, Feb. 1990, pp. 260-265.
Westermark et al., Proc. Natl. Acad. Sci. U.S.A. 84:3881-85 (1987).
Cooper et al., Proc. Natl. Acad. Sci. U.S.A. 84:8628-32 (1987).
Joslin's Diabetes Mellitus, Chapter 21 (12th ed. 1985).
Goodman and Gilman's: The Pharmacological Basis of Therapeutics, p. 1504 (7th ed. 1988).
Nishi et al., Journal of Biological Chemistry 265:4173-76 (1990).
Clark, Diab. Med. 6:561-67 (1989).
Cooper et al., Biochim. Biophy. Acta 1014:247-58 (1989).
Cooper et al., Diabetes 1988, pp. 493-496, Larkins, Zimmet, and Chisholm (Eds.), (Elsevier Science Publishers B. V. 1989).
Cooper et al., Progress in Growth Factor Research 1:99-105 (1989);
Johnson et al., New England Journal of Medicine 321:513-18 (1989).
Cooper Garth J. S.
Moore Candace X.
Amylin Pharmaceuticals Inc.
Russel Jeffrey E.
LandOfFree
Hypoglycemics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hypoglycemics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hypoglycemics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1142774